Kooperativer Bibliotheksverbund

UID:

Umfang: 1 online resource (496 pages)

ISBN: 0-12-823687-6

Anmerkung: Front Cover -- Nanotherapeutics in Cancer Vaccination and Challenges -- Nanotherapeutics in Cancer Vaccination and Challenges -- Copyright -- Dedication -- Contents -- List of contributors -- Preface -- Acknowledgments -- 1 - Cancer vaccines: past, present, and future -- 1. Introduction -- 2. Cancer vaccines and their applications -- 3. Smart carriers in cancer vaccine delivery -- 3.1 Nanoparticles -- 3.2 Liposomes -- 3.3 Nanoemulsions -- 3.4 Magnetic nanoparticles -- 3.5 Niosomes -- 3.6 Bilosomes -- 3.7 Archeosomes -- 3.8 Microspheres -- 3.9 Viral nanovectors -- 3.10 Immuno potentiating virosomal carriers -- 4. Key challenges: formulation challenges and regulatory hurdles -- 5. Conclusion and future perspectives -- References -- 2 - Inorganic nanoparticulate carriers in management of cancer: theranostics and toxicity apprehension -- 1. Introduction -- 2. Inorganic nanoparticles -- 2.1 QD -- 2.2 Gold nanoparticles -- 2.3 Magnetic nanoparticles -- 2.4 Mesoporous silica nanoparticles (MSNPs) -- 2.5 Aluminum-based nanoparticle -- 2.6 Calcium-based nanoparticle -- 2.7 Carbon nanoparticle -- 3. Advantages of inorganic nanoparticle -- 4. Application of inorganic nanoparticles in cancer treatment -- 4.1 Toxicity -- 5. Conclusion -- References -- 3 - Recent developments in cancer vaccines: where are we? -- 1. Introduction -- 2. Vaccines and their mechanism of action -- 3. Classification of cancer vaccine -- 3.1 Prophylactic vaccine -- 3.2 Autologous tumor cell vaccine -- 3.3 Allogenic tumor cell vaccine -- 3.4 Dendritic cell (DC) vaccine -- 3.5 Protein/peptide-based vaccine -- 3.6 Genetic vaccine -- 3.6.1 DNA vaccine -- 3.7 RNA vaccine -- 4. The fundamental mechanism of antitumor immunity -- 5. Cancer and its types -- 5.1 Breast cancer -- 5.2 Liver cancer -- 5.3 Lung cancer -- 5.4 Bladder cancer -- 5.5 Colorectal cancer -- 5.6 Leukemia. , 5.7 Prostate cancer -- 5.8 Pancreatic cancer -- 5.9 Melanoma -- 5.10 Kidney cancer -- 6. Present cancer treatments -- 6.1 Surgery -- 6.2 Radiation therapy -- 6.3 Chemotherapy -- 6.4 Targeted therapy -- 6.4.1 Immunotherapy -- 6.5 Hormone therapy -- 6.6 Stem cell therapy -- 7. Significance of the development of cancer vaccine -- 8. Known or possible targets for the development of cancer vaccines -- 9. Current status on the development of cancer vaccines -- 9.1 Preclinical studies on vaccine developments -- 9.2 Clinical studies on vaccine developments -- 10. Future perspectives of cancer vaccines -- 11. Conclusion -- 12. Conflict of interest -- Acknowledgments -- References -- 4 - Application of nanotechnology assisted devices in cancer treatment -- 1. Introduction -- 2. Nanotechnology in cancer -- 3. Devices based on nanotechnology -- 4. Nanotechnology and medical devices -- 5. Emerging medical devices using nanotechnology for cancer therapy -- 6. Challenges and regulations -- 7. Advantages and disadvantages of nanotechnology in cancer -- 7.1 Disadvantages of nanotechnology -- 8. Conclusion -- 9. Conflict of interest -- Acknowledgments -- References -- 5 - Advancement in protein-based nanocarriers in targeted anticancer therapy -- 1. Introduction -- 2. Protein-based nanocarriers in targeted drug delivery -- 2.1 Albumin based nanocarriers against solid tumors -- 2.2 PEGylated based gelatin containing nanocarriers -- 2.3 Casein-based nanocarriers against targeted action for tumor -- 2.4 Zein-based nanocarriers against breast cancer -- 2.5 Gliadin nanocarriers against tumor targeted drug delivery -- 2.6 Conclusion -- References -- Further reading -- 6 - Elastic liposomes as transcutaneous DNA vaccine vectors -- List of abbreviations -- 1. Introduction: brief history of vaccinology and focus on DNA vaccines -- 2. Need for targeted DNA vaccines. , 3. Liposomes as DNA vaccine vectors -- 4. The skin as an immunization route -- 5. Topical application of DNA vaccines and optimization of material delivery through colloidal vectors -- 6. Conclusions -- References -- 7 - Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies -- 1. Introduction -- 2. Mechanism of action conciliated by the interaction between nanoparticles (NPs) and dendritic cells (DCs) -- 3. Potential change in pharmacological effects -- 4. Potential effects of NPs on DCs -- 4.1 NPs affect maturation process of DC -- 4.1.1 NPs affect homing capability of DCs -- 4.1.2 NPs weaken antigen-processing capability (APC) of DCs -- 4.1.3 NPs affect T cell differentiation induced by DC -- 4.2 Limitation and challenges immunotherapy strategies -- 4.3 Key issues summarization as given below keeping in mind with the all aspects -- 5. Conclusion -- References -- 8 - Peptide-based anticancer targeted therapeutics: state of the art -- 1. Introduction -- 2. Peptide-based anticancer targeted therapeutics -- 2.1 Tumor homing peptides (THPs) -- 2.2 CTPs (cell-targeting peptides) in cancer -- 2.3 CPPs: cell-penetrating peptides -- 2.3.1 Modifications of CPPs -- 2.3.2 Different types of CPPs used in cancer therapy -- 2.3.2.1 Self-assembly CPPs -- 2.3.2.2 Sweet arrow peptides (SAP) -- 2.3.2.3 Antimicrobial peptides (AMP) -- 2.3.2.4 TAT peptide -- 2.3.2.5 RGD peptide -- 2.3.2.5.1 RGD polymers and nanoparticles -- 2.3.3 Targeting peptides in cancer gene therapy -- 3. Future perspectives and conclusion -- References -- Further reading -- 9 - Polyplexes-based delivery systems for cancer vaccine delivery -- 1. Introduction -- 2. Cancer vaccines -- 2.1 Vaccines for cancer prevention -- 2.2 Vaccines for cancer treatment -- 2.3 Commonly used cancer vaccines vectors (viral and nonviral). , 2.4 Cancer vaccine and its mechanism of action in immune system -- 2.5 Drawback associated to the use of cancer vaccine -- 3. Nanotechnology based carrier system for cancer vaccine delivery -- 4. Polyplexes -- 4.1 Structure of polyplexes -- 4.2 Methods for preparation of polyplexes -- 4.2.1 Preparation of polyplexes by microfluidics -- 4.2.2 Preparation of chitosan-DNA polyplexes -- 4.3 Mode of action of polyplexes in the body cell -- 4.3.1 Step I: cell binding and uptake -- 4.3.2 Step II: escape from endosome -- 4.3.3 Step III: dissociation of polyplexes -- 4.3.4 Step IV: nuclear import -- 4.4 Different types of polymers in polyplexes -- 4.4.1 Poly(l-lysine) -- 4.4.2 Poly(ethylenimine) -- 4.4.3 Poly (lactic-co-glycolic) acid -- 4.4.4 Poly(amidoamine) -- 4.4.5 Pluronic block copolymers -- 4.4.6 Other miscellaneous polymers -- 5. Characterization of polyplexes -- 6. Applications of lipoplexes and polyplexes -- 7. Conclusion -- References -- 10 - Lipopolyplex-based delivery system for cancer vaccine delivery -- 1. Introduction -- 2. Lipopolyplex structure and physicochemical properties -- 3. Types of cancer vaccine -- 3.1 Tumor cell vaccines -- 3.1.1 Autologous vaccines -- 3.1.2 Allogenic vaccines -- 3.2 Dendritic cell vaccines -- 3.3 Protein or peptide based cancer vaccine -- 3.4 Genetic vaccines -- 3.4.1 DNA vaccines -- 3.4.2 RNA vaccines -- 4. Therapeutic cancer vaccine targeted delivery -- 5. Advantages of lipopolyplex based delivery -- 6. Limitations -- 7. Conclusion -- References -- 11 - Inorganic nanoparticulate carriers in cancer vaccination -- 1. Introduction -- 2. Cancer immunotherapy -- 2.1 Cancer immunity cycle: a cascade in response to the tumor antigen -- 2.2 Tumor antigens: a trigger for immune response -- 3. Nanomedicine: unmet need in cancer immunotherapy -- 3.1 Nanomaterials for cancer vaccine -- 3.2 Inorganic naomaterials. , 3.3 Inorganic nanoparticles for cancer immunotherapy -- 3.4 Aluminum -- 3.5 Iron -- 3.6 Silica -- 3.7 Gold -- 3.8 Calcium -- 3.9 Copper -- 3.10 Cobalt -- 3.11 Silver -- 3.12 Zinc -- 3.13 Challenges for translating inorganic nanoparticle -- References -- 12 - Functional nanomaterials and nanocomposite in cancer vaccines -- 1. Generally employed vaccines and antigens for anticancer therapy -- 2. Identified tumor-associated antigens -- 3. Whole tumor cells or tumor lysates -- 4. DNA vaccines -- 5. Subunit peptide vaccine -- 6. mRNA vaccine -- 7. Personalized vaccine and neoantigen -- 8. Functional nanomaterials -- 9. Liposomal nanovaccine -- 10. PLGA nanovaccine -- 11. Dendrimers nano vaccine -- 12. Approved cancer vaccines: for treatment and prevention -- 12.1 TheraCys and TICE -- 12.2 Provenge -- 12.3 IMLYGIC -- 13. Cancer vaccines approved for chemoprevention [68] -- 13.1 Cervarix -- 13.2 Gardasil -- 13.3 Gardasil-9 -- 13.4 HEPLISAV-B -- 14. Conclusion -- References -- 13 - DNA vaccines for cancer treatment: challenges and promises -- 1. Introduction -- 1.1 Cancer antigens -- 1.2 DNA vaccines and mechanism of action -- 1.2.1 Mechanism of immune activation by DNA vaccines -- 1.3 Advantages and limitations of DNA vaccines -- 1.4 Approaches toward optimal priming -- 1.5 Approaches toward DNA vaccine design to circumvent immune tolerance -- 2. Nano-carriers for transfer of DNA vaccines -- 2.1 Nanocarriers composed of inorganic materials -- 2.2 Lipid-based nanocarriers -- 2.3 Protein based nanocarriers -- 2.4 Polymeric nano carriers -- 3. Conclusion -- References -- 14 - mRNA-based nanovaccines as newer treatment modalities in cancer -- 1. Introduction -- 2. mRNA nanovaccines in cancer: stability manifestations -- 2.1 Barriers to entry of mRNA nanovaccine into cell: interaction mystification -- 2.1.1 mRNA nanodelivery via systemic administration. , 2.1.2 mRNA nanodelivery via subcutaneous administration.

Weitere Ausg.: Print version: Rahman, Mahfoozur Nanotherapeutics in Cancer Vaccination and Challenges San Diego : Elsevier Science & Technology,c2022 ISBN 9780128236864

Sprache: Englisch